AbbVie saw an average 21% year-over-year increase in sales across its aesthetics and neuroscience portfolios, led by strong demand for Botox Cosmetic, Juvederm, and the newly launched oral migraine drug, Ubrelvy. Rising interest rates and strong demand, coupled with sellers looking to cash in on high prices is creating an environment where houses barely stay on the market for a few days, if even listed publicly at all. On May 5, Parker provided upward revised revenue guidance for fiscal 2022 despite headwinds from COVID-related shutdowns in China, growing inflationary pressures, supply chain disruption, and labor force challenges.